TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›FTH›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Sensei Biotherapeutics, Inc. (FTH) financials

Income statement

Sensei Biotherapeutics, Inc. (FTH) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$19.5M-$37.5M-$50.2M-$37.1M-$32.6M-$22.3M
Net income-$20.1M-$36.8M-$48.6M-$34.1M-$30.2M-$21.1M
EPS (diluted)-$12.53-$1.33-$1.58-$1.22-$24.01-$16.72

Cash flow

Sensei Biotherapeutics, Inc. (FTH) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$17.7M-$30.3M-$39.0M-$32.0M-$24.7M-$20.5M
Capital expenditures$1.21M$2.03M$321K$180K$146K$16.0K
Free cash flow-$18.9M-$32.3M-$39.3M-$32.2M-$24.8M-$20.5M
Share buybacks———$10.4M——

Balance sheet

Sensei Biotherapeutics, Inc. (FTH) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$16.6M$7.16M$17.8M$13.0M$9.99M$8.67M
Total assets$21.4M$153M$118M$74.4M$45.4M$22.9M
Total liabilities$5.54M$6.71M$15.0M$9.48M$6.97M$4.31M
Long-term debt$567K—————
Shareholders' equity-$56.4M$147M$103M$64.9M$38.4M$18.6M
Retained earnings-$112M-$149M-$198M-$232M-$262M-$283M
Shares (wtd avg diluted)1.88M27.7M30.7M28.0M1.26M1.26M

Every figure is extracted from Sensei Biotherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Sensei Biotherapeutics, Inc.'s free cash flow?
-$20.5M in FY2025 (operating cash flow -$20.5M minus $16.0K of capital expenditures), from the SEC cash-flow statement.
Does FTH pay a dividend?
Sensei Biotherapeutics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full FTH analysis — verdict, score & filings →Is FTH a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.